This invention provides a human-derived genetic engineering antibody that can specifically bond avian influenza virus H5N1. The genetic engineering antibody is derived from antibody gene library of avian influenza virus H5N1 patients in convalescence. The recombinant antibody is decided by hypervariable region (CDRs) specific gene sequence in the antibody light chain and heavy chain gene variableregion, and is effectively expressed in procaryotic cells and eukaryotic cells. The recombinant antibody is a functional neutralizing antibody can specifically bond avian influenza virus haemagglutinin protein HA. Part or all genes of the antibody in CDR can modify and produce genetic engineering antibodies with different forms in procaryotic cells, yeast, insects and eukaryotic cells, and can prevent and treat diseases related to avian influenza virus H5N1.